Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor + Lenvatinib vs Regorafenib in Advanced HCC After 1L Failure
NCT07537985Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of lenvatinib and regorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Overall Survival at 6 months and Progression-Free Survival at 6 months. Started Jan 2020; status: completed.
02
Drugs
lenvatinibregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07537985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537985.